Government Initiatives to Curb down the CVDs to Creates Scope for European Nanomedicine Market Growth

The European Nanomedicine market is anticipated to grow significantly at a CAGR of 10.9% over the forecast period (2021-2027). The UK, Germany, France, Italy, Spain, and the Rest of Europe are some of the key economies that are substantially contributing to the growth of the European nanomedicine market over the forecast period. The key aspect that drives the growth of the European nanomedicine industry is the rise in the prevalence of various severe diseases such as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and other diseases. EU countries have a huge pool of CVD patients that creates scope for the growth of the market.

Browse the full report description European Nanomedicines Market Size, Share & Trends Analysis Report By Indication Type (Cardiovascular Diseases, Neurological Diseases, Infectious Diseases, Oncological Diseases, Orthopedic Diseases, and Other Diseases (Urological Disease, Ophthalmic Diseases)), and by Application (Drug Delivery, Active Implants, Vaccines, Diagnostic Imaging, Biomaterials, Regenerative Medicines, and Other Applications (Tissue Regeneration)) Forecast, 2021-2027 at https://www.omrglobal.com/industry-reports/europe-nanomedicines-market

Further, rising government funding for the development of advanced treatment solutions, key activities done by the players, along with the various plans initiated by the government. The European Stroke Organization (ESO) and Stroke Alliance for European (SAFE) published European Stroke Action Plan (ESAP) in May 2018. The aim of the plan to set a roadmap and goals for the treatment of stroke in Europe by 2030. Furthermore, the presence of various key players such as 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others also support the growth of the market over the forecast period.

Market Coverage

• Market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- By Indication Type and By Applications
• Region Covered- European
• Competitive Landscape- 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in base year?
• Which segment will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

European Nanomedicine Market – Segmentation

By Indication Type

• Cardiovascular Diseases
• Neurological Diseases
• Infectious Diseases
• Oncological Diseases
• Orthopedic Diseases
• Other Diseases (Urological Disease, Ophthalmic Diseases)

By Application

• Drug Delivery
• Active Implants
• Vaccines
• Diagnostic Imaging
• Biomaterials
• Regenerative Medicines
• Other Applications (Tissue Regeneration)

European Nanomedicine Market – Countries Covered

Europe

• The UK
• Germany
• France
• Italy
• Spain
• Rest of Europe